ABSTRACT
Mucormycoses, caused by the mucormycetes molds, are known to cause life- threatening angioinvasive infection, such as rhinocerebral disease. The manifestations of this infection depend on the underlying condition of the host. Patients with diabetes mellitus, hematological malignancies, and bone marrow transplant recipients are particularly at risk for this infection. Therefore, therapy heavily relies on controlling the underlying host disease. Treatment often also involves surgical debridement of fungal invaded and devitalized tissue followed by systemic antifungal therapy with polyenes and possibly, azoles, and combinations of these classes with echinocandins. In this chapter, we discuss these three therapeutic areas and also highlight some emerging adjunctive therapies such as the use of GM-CSF, hyperbaric oxygen, and iron chelation therapy.
